Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 5.5% – Time to Sell?

Posted by Brian Himes on Aug 6th, 2026

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Free Report)’s share price fell 5.5% on Tuesday . The company traded as low as $8.80 and last traded at $8.4870. Approximately 99,811 shares changed hands during trading, a decline of 92% from the average daily volume of 1,219,235 shares. The stock had previously closed at $8.98.

Analyst Ratings Changes

A number of brokerages have weighed in on PHAT. HC Wainwright restated a “buy” rating and issued a $26.00 target price on shares of Phathom Pharmaceuticals in a research note on Friday, July 31st. Guggenheim lowered their price target on Phathom Pharmaceuticals from $25.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research report on Friday, July 17th. Needham & Company LLC cut their price objective on shares of Phathom Pharmaceuticals from $28.00 to $22.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Finally, Craig Hallum reiterated a “buy” rating and issued a $20.00 price objective on shares of Phathom Pharmaceuticals in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.43.

View Our Latest Analysis on Phathom Pharmaceuticals

Phathom Pharmaceuticals Trading Down 2.6%

The firm has a market cap of $665.82 million, a P/E ratio of -6.43 and a beta of 0.51. The business’s fifty day simple moving average is $10.62 and its 200-day simple moving average is $11.54.

Institutional Trading of Phathom Pharmaceuticals

Several large investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd purchased a new stake in Phathom Pharmaceuticals in the 4th quarter worth approximately $27,000. Raymond James Financial Inc. purchased a new position in shares of Phathom Pharmaceuticals during the second quarter valued at approximately $30,000. Summit Securities Group LLC purchased a new position in shares of Phathom Pharmaceuticals during the first quarter valued at approximately $34,000. Kestra Advisory Services LLC bought a new position in shares of Phathom Pharmaceuticals during the fourth quarter valued at approximately $38,000. Finally, BNP Paribas Financial Markets raised its holdings in shares of Phathom Pharmaceuticals by 71.9% during the second quarter. BNP Paribas Financial Markets now owns 5,072 shares of the company’s stock valued at $49,000 after acquiring an additional 2,122 shares in the last quarter. 99.01% of the stock is owned by institutional investors.

Phathom Pharmaceuticals Company Profile

(Get Free Report)

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.